Evaluating eligibility criteria of oncology trials using real-world data and AI
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evaluating eligibility criteria of oncology trials using real-world data and AI
Authors
Keywords
-
Journal
NATURE
Volume 592, Issue 7855, Pages 629-633
Publisher
Springer Science and Business Media LLC
Online
2021-04-08
DOI
10.1038/s41586-021-03430-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database
- (2019) Gillis Carrigan et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
- (2019) Yi-Long Wu et al. Journal of Thoracic Oncology
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
- (2019) Sean Khozin et al. CANCER
- An AI boost for clinical trials
- (2019) Marcus Woo NATURE
- Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative
- (2018) Grant D. Huang et al. Contemporary Clinical Trials
- Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
- (2018) Melissa D. Curtis et al. HEALTH SERVICES RESEARCH
- Electronic medical records can be used to emulate target trials of sustained treatment strategies
- (2018) Goodarz Danaei et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Target trial emulation: teaching epidemiology and beyond
- (2017) Jeremy A. Labrecque et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
- (2017) Edward S. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Automated classification of eligibility criteria in clinical trials to facilitate patient-trial matching for specific patient populations
- (2017) Kevin Zhang et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- EliIE: An open-source information extraction system for clinical trial eligibility criteria
- (2017) Tian Kang et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
- (2017) Amy P. Abernethy et al. PLoS One
- Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials
- (2017) Siddhartha R. Jonnalagadda et al. Journal of Cardiovascular Translational Research
- Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials
- (2016) Anando Sen et al. Annals of the New York Academy of Sciences
- Will they participate? Predicting patients’ response to clinical trial invitations in a pediatric emergency department
- (2016) Yizhao Ni et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Increasing the efficiency of trial-patient matching: automated clinical trial eligibility Pre-screening for pediatric oncology patients
- (2015) Yizhao Ni et al. BMC Medical Informatics and Decision Making
- Textual inference for eligibility criteria resolution in clinical trials
- (2015) Chaitanya Shivade et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Modernizing Eligibility Criteria for Molecularly Driven Trials
- (2015) Edward S. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Caicun Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- Case-based reasoning using electronic health records efficiently identifies eligible patients for clinical trials
- (2015) R. Miotto et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Immortal Time Bias in Pharmacoepidemiology
- (2007) S. Suissa AMERICAN JOURNAL OF EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation